Document is current
Any future updates will be listed below
-
Authors
Foss-Freitas, Maria
Gilio, Donatella
Oral, Elif A.
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK125513, DK125513, DK125513)
Lipodystrophy Research Fund at University of Michigan
Caswell Diabetes Institute of University of Michigan
Rejuvenate Bio
Università di Pisa
- License Information
-
More Information
Article History
Accepted: 31 July 2025
First Online: 21 August 2025
Declarations
:
: Dr. Elif A. Oral In the lipodystrophy space consults with and receives clinical trial and grant support from Amryt Pharmaceuticals now part of Chiesi, Regeneron Pharmaceuticals and Ionis Pharmaceuticals. She consults with Third Rock Ventures (now formed Marea Therapeutics) and Rejuvenate Inc. Grant money from PTC Therapeutics was also received in the last 2 years. She also has IP rights to metreleptin manufactured by Amryt Pharmaceuticals, now part of Chiesi and is entitled to royalty payments. Unrelated to lipodystrophy, Dr. Oral has ongoing clinical trial support from Novo Nordisk, Rhythm Pharmaceuticals, and Morphic Medical (formerly GI Dynamics). The other authors report no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
